RIS Rx, a healthcare technology company offering gross-to-net (GTN) revenue protection and saving more than $1 billion for the world’s leading pharmaceutical manufacturers, today announced the appointment of Stuart McGuigan to its Board of Directors.

Mr. McGuigan is an expert technology and healthcare executive with more than three decades of experience driving digital transformation and operational excellence in complex global organizations. Most recently, he served as Interim Global Chief Information Officer for Fresenius Medical Care, where he oversaw technology strategy and execution across the company’s global dialysis and renal care operations. Prior to this role, Mr. McGuigan was Chief Information Officer of the U.S. Department of State, where he established strategic direction and provided oversight for multibillion-dollar technology programs. Prior to that, he led global information technology for Johnson & Johnson and held senior technology leadership roles at CVS Caremark, Liberty Mutual and Medco Health Solutions. Mr. McGuigan also serves on multiple boards, including Enhabit Home Health & Hospice, American Water and Fairfield University’s John Charles Meditz College of Arts and Sciences, and he is widely recognized for aligning technology innovation with organizational strategy to drive measurable business results.

“RIS Rx’s mission to bring transparency and accountability to the GTN process is vital to advancing patient access,” said Gerard Rivera, CEO and Co-Founder of RIS Rx. “Stuart’s deep expertise in technology innovation and strategic leadership across healthcare and global enterprises will be an invaluable asset as we continue to scale the company’s platform and deliver differentiated value for our pharmaceutical manufacturer customers.”

“I am honored to join the Board of RIS Rx at such an exciting stage,” said Stuart McGuigan. “The company’s commitment to tackling inefficiencies in how financial support reaches patients resonates deeply with me, and I look forward to supporting RIS Rx’s growth and innovation alongside Gerard and the rest of the Board.”

About RIS Rx

RIS Rx is a healthcare technology company delivering gross-to-net (GTN) revenue protection for the world’s leading pharmaceutical manufacturers. Through proprietary software, real-time analytics and pharmacist-led expertise, RIS Rx helps clients optimize operations, eliminate leakage and ensure that financial assistance reaches the patients who need it most. In 2025 alone, the company has protected more than $1 billion in revenue for its customers. Founded in 2020 and headquartered in Irvine, California, RIS Rx serves leading pharmaceutical manufacturers across a growing portfolio of drug brands. Learn more at www.RISRx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251217121293/en/